MANILA, Philippines — The e-travel form of the Philippines will now include screening questions that would help authorities prevent the entry of mpox (formerly monkeypox) into the country.

The Department of Health (DOH) said Thursday that travelers coming from abroad who have been sick within the past month must now indicate in their e-travel form if they experienced “rashes, vesicles, or blisters” as the government boosted efforts to curb the spread of mpox.

“To aid in preventing the entry of additional mpox cases from abroad, particularly clade Ib, there has been just one small yet significant change in the screening questions of the DOH Bureau of Quarantine (BOQ) asked of travelers, as part of the electronic travel form,” it explained in a statement.

“Should a traveler answer yes when asked if they have been sick in the past 30 days, the drop down list will now include the option ‘rashes, vesicles, or blisters.’ It is important for all travelers to be honest in answering this question,” it added.

Clade Ib is the sub-clade of MPXV clade I which has been described in the 1980s as having a mortality rate ranging from one percent to 10 percent.

The other type, MPXV clade II, has been observed mainly in West Africa, and it has a mortality rate of less than one percent to four percent.

The DOH explained that if the traveler is determined to be from a country with an mpox outbreak, have a history of exposure to mpox cases, or exhibit signs and symptoms of the disease, then the etravel.gov.ph system will alert the Bureau of Immigration and the DOH-BOQ.

He or she will undergo a second screening and, if ever determined to be a suspected case, be transferred to an mpox referral hospital.

According to the Centers for Disease Control and Prevention (CDC), among the symptoms of mpox are fever, swollen lymph nodes, muscle ache, and rashes that may be located on hands, feet, chest, face, or mouth or near the genitals.

Symptoms typically manifest 21 days after exposure to the virus.

The mpox virus can spread through contact with objects and surfaces that have not been disinfected after use by someone with mpox, the CDC also said.

On Wednesday, the DOH reported the detection of two more mpox cases. Currently, the total number of mpox cases in the Philippines stood at 14 since July 2022.

But the DOH noted that only five of the 14 cases remain active and that the patients carry the milder type MPXV clade II.

The newly detected cases are a 26-year-old female from the National Capital Region or Metro Manila and a 12-year-old male from Calabarzon.

Source:  https://globalnation.inquirer.net/247127/ph-e-travel-form-now-includes-mpox-screening-questions-says-doh

Bitchute: https://www.bitchute.com/channel/YBM3rvf5ydDM/

Gab: https://gab.com/hopegirl

Telegram: https://t.me/Hopegirl587

EMF Protection Products: www.ftwproject.com

QEG Clean Energy Academy: www.cleanenergyacademy.com

Forbidden Tech Book: www.forbiddentech.website

The post Philippines Travelers must screen for Mpox appeared first on HopeGirl Blog.

Leaders in Bali are stepping up the Mpox screening process for all international arrivals into I Gusti Ngurah Rai International Airport.

In the last few weeks, Indonesia has introduced new screening measures, including arrival forms and thermal imaging cameras; now, tourists must download the Ministry of Health’s smartphone app.

On the 18th of August, the Acting Director General of Disease Prevention and Control at the Ministry of Health, Yudhi Pramono, released a statement to confirm that all international arrivals at all Indonesian airports would be required to fill in a questionnaire form to be submitted at their arrivals terminal.

This was in response to statements issued by the World Health Organisation that declared recent outbreaks of Mpox as a public health emergency of international concern. 

Heryudhitiawan assured passengers that this was a preventative measure and that the thermal screening was not targeting travelers from any particular destination or demographic. 

It has been confirmed by the Ministry of Transportation (Kemenhub) that it is now a travel requirement for overseas travelers to use the SatuSehat application. Sahu means one and sehat means health.

This is the same government health monitoring app that was used in the months following the reopening of borders during the COVID-19 pandemic.

In a written statement published on Wednesday, 28th August, the Director General of Air Transportation, M. Kristi Endah Murni, explained: “The determination of SE 5 DJPU in 2024 is a guide for Air Transport Business Entities and Foreign Air Transport Companies so that every person (flight personnel and passengers) of foreign travelers who fly to Indonesia to fill out an electronic self-declaration form called SATUSEHAT Health Pass, as well as a guide for International Airport Operators to take measures to prevent and handle the transmission of Mpox disease at the airport.”

He added, “I have ordered the Director of Aviation Safety and the Head of the Airport Authority Office to supervise the implementation of the Circular Letter. All parties are to be able to carry out the work with full responsibility.”

The app can be downloaded from the Apple App Store or the Google Store for Android users. The app is available in English.

Murni has issued further guidance to the aviation and travel industry across Indonesia to help prevent the spread of the virus in the country.

This guidance includes instructions to “Socialize and inform everyone (flight personnel and passengers) who travel abroad who fly to Indonesia to fill out the SATUSEHAT Health Pass electronic self-declaration form on the domain: https://sshp.kemkes.go.id.”

The circular letter also outlines the need for airport and airline staff to supervise tourists by” filling out the SATUSEHAT Health Pass electronic self-declaration form for every person (flight personnel and passengers) who travel abroad, which is done at the departure airport.”

The third and fourth instructions are focused on health professionals and travel operators but are worth noting.

Officials have instructed that authorities must “Coordinate with the Health Quarantine Centre if there is a problem in filling out the electronic self-declaration form SATUSEHAT Health Pass at the arrival airport; and coordinate with the Health Quarantine Center in the framework of efforts to prevent the transmission of Mpox disease in Indonesia.”

The Mpox screening measures for tourists visiting Bali are being implemented particularly quickly since the province is preparing to host the Indonesia-Africa Forum 2024 from the 1st to the 3rd of September.

In a separate statement, the Deputy Minister of Health, Dante Saksono Harbuwono, explained that the health screening measures are a method of ensuring everything continues to run smoothly for tourists and local communities in the province.

He explained that plans are in place for every eventuality. Harbuwono shared, “We and the Health Quarantine Center have determined the screening scenario, starting from the placement of screening tools, the PCR (swab test) room, and questionnaires to the process of referring to hospitals.”

He added, “After the scenario that we applied and tried to simulate today, we have determined the place where the swab test will be carried out, where the thermal scanner will be installed, and where the questionnaire is so that all can be identified correctly and not disturb other passengers.”

Source:  https://thebalisun.com/tourists-must-download-mpox-tracing-app-before-bali-travel/

Bitchute: https://www.bitchute.com/channel/YBM3rvf5ydDM/

Gab: https://gab.com/hopegirl

Telegram: https://t.me/Hopegirl587

EMF Protection Products: www.ftwproject.com

QEG Clean Energy Academy: www.cleanenergyacademy.com

Forbidden Tech Book: www.forbiddentech.website

The post Tourists Must Download Mpox Tracing App Before Bali Travel appeared first on HopeGirl Blog.

The South Africa “Vaccine” Injury Medico-Legal Study Group (“SAVIMS”) has released a press statement to say that it does not support the Africa CDC and World Health Organisation declaration of a global health emergency for monkeypox, now known as mpox.

Additionally, they have warned about the recommended live virus vaccines, Jynneos and ACAM2000: The vaccines are experimental use for monkeypox, as they were originally intended for smallpox; there are reported serious adverse effects; and, they contain live viral strains, which may potentially instigate a resurgence of the eradicated smallpox virus.

“We warn members of the public about the inherent risks of taking any vaccine, including those proposed for mpox, of which the effectiveness and safety have not been reliably determined … There can be no justification for a vaccine with unknown adverse effects,” SAVIMS says.

Furthermore, SAVIMS emphasises the need for independent auditing of the collated monkeypox data in the Democratic Republic of Congo (“DRC”) and other African countries, as provided by the WHO, to ensure the accuracy and reliability of the statistics and analysis.

SAVIMS is a voluntary multidisciplinary association whose purpose is to follow the evidence, to gain and communicate knowledge about vaccine injuries.  Its objectives are to promote human health and human rights as enshrined in the Bill of Rights of the Constitution of the Republic of South Africa.  SAVIMS’ website is not yet live.  Yesterday, James Roguski published the press statement below from SAVIMS.

SAVIMS

Johannesburg, South Africa – 18 August 2024

IMMEDIATE RELEASE: Statement on proposed emergency roll-out of vaccine program in Africa for monkeypox

We are deeply concerned about the recent announcements made by Africa CDC Director General Jean Kaseya on 13 August 2024 and WHO Director-General Tedros Adhanom Ghebreyesus on 14 August 2024. It is important to address these announcements openly to the public. In his statements, Director General Jean Kaseya declared regarding monkeypox vaccines, “We have a clear plan to secure more than 10 million doses in Africa, starting with 3 million doses in 2024.”

We at SAVIMS would like to point out pertinent facts to both institutions and other relevant bodies of interest:

1. There is no prescribed vaccine with documented Level 1 scientific evidence for monkeypox. The current WHO recommended live virus vaccines, Jynneos and ACAM2000, are (a) intended for smallpox and are thus experimental for monkeypox; (b) have reported serious adverse effects and (c) contain live viral strains which may instigate a resurgence of the eradicated smallpox virus.

2. The potential use of mRNA vaccines. There is no scientific evidence supporting the use of any mRNA vaccine to prevent or mitigate any infectious disease. The observed data of adverse reactions to experimental mRNA vaccines far outweighs any benefit.

3. Informed consent is an ethical concept that is codified in the law and is in daily practice at every healthcare institution. Three fundamental criteria are needed for clinical informed consent: the patient must be competent, adequately informed, and not coerced. It is not possible for any recipient of these vaccines to receive a legitimate informed consent based on the current research.

4. The article by Allan-Blitz et al, ‘A position statement on Mpox as a Sexually Transmitted Disease’, concluded that monkeypox is a sexually transmitted disease. Preventative measures for this scenario should necessitate and provoke relevant clinical and primary health care and education initiatives directed at the high-risk group. There is no merit for the recommendation of experimental vaccines to the general population.

5. The statistics and analysis, regarding the collated monkeypox data in the DRC and other countries in Africa by the WHO, warrant further investigation, and must be independently audited. The areas in which the highest statistics were collated should detail the criteria for testing, the procedures for testing, equipment sensitivity and specificity, personnel skill, clinical scenarios, and provocation for testing these specific communities. What tests were done to investigate and exclude other diseases, including communicable diseases?

6. There have been no autopsy reports published on the deaths related to monkeypox. The lack of formal documented autopsy, lack of information regarding equipment test sensitivities and specificities, and lack of information on procedures validating random collation of data, further reduces and invalidates the authenticity of the statistics.

SAVIMS Position Statement Regarding Emergency Monkeypox Vaccine Rollout in Africa:

We have reviewed the literature and analysed the data on monkeypox, as well as its etiopathogenesis. Based on our understanding of this disease:

A. We do not support the Africa CDC and WHO declaration of a global health emergency for monkeypox.

B. It is established that monkeypox is predominantly a self-limiting condition. This does not warrant vaccine intervention.

C. We strongly object, based on the scientific evidence, to the “emergency” rollout of repurposed smallpox vaccines or any other proposed monkeypox vaccine to the people of Africa.

D. We question the authenticity of the number of deaths associated with monkeypox, as reported by the Africa CDC, unless it can be verified through autopsy.

E, We warn members of the public about the inherent risks of taking any vaccine, including those proposed for mpox, of which the effectiveness and safety have not been reliably determined by Level 1 clinical trials. There can be no justification for a vaccine with unknown adverse effects.

F. We urge the public to exercise their inherent human rights to refuse to give consent to any medical intervention that they do not feel comfortable in taking.

We are open to dialogue and discussion with the Africa CDC on the issues raised above and on all matters of health and well-being concerning the African population.

SAVIMS Board

Contact: Dr Edeling, Chair

For further enquiries eMail: savims@savims.org.za

Supporting references:

• Allan-Blitz LT, et al. A Position Statement on Mpox as a Sexually Transmitted Disease. Clin Infect Dis. 2023 Apr 17;76(8):1508-1512
• Bloch DA. Comparing two diagnostic tests against the same “gold standard” in the same sample. Biometrics. 1997 Mar;53(1):73-85. Erratum in: Biometrics 1998 Mar;54(1):399.
• Cocanour CS. Informed consent-It’s more than a signature on a piece of paper. Am J Surg. 2017 Dec;214(6):993-997.
• Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015 Feb 26;372(9):855-62.
• https://africacdc.org/news-item/speech-of-the-director-general-africa-cdc-on-the-declaration-of-mpox-as-a-public-health-emergency-of-continental-security-phecs/
• https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-ihr-emergency-committee-meeting-regarding-the-upsurge-of-mpox-2024—14-august-2024
• https://www.who.int/health-topics/smallpox
• https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html
• https://jynneos.com/
• https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox–external-situation-report-35–12-august-2024
• https://clinicaltrials.gov/study/NCT05988203?term=NCT05988203&rank=1
• https://clinicaltrials.gov/search?term=mrna%20vaccine
• Ogoina D, et al. Clinical review of human mpox. Clin Microbiol Infect. 2023 Dec;29(12):1493-1501.
• Zidan M, et al. What you need to know about statistics, part II: reliability of diagnostic and screening tests. Pediatr Radiol. 2015 Mar;45(3):317-28.

Source:  https://expose-news.com/2024/08/22/south-african-group-refutes-whos-declaration/

Bitchute: https://www.bitchute.com/channel/YBM3rvf5ydDM/

Gab: https://gab.com/hopegirl

Telegram: https://t.me/Hopegirl587

EMF Protection Products: www.ftwproject.com

QEG Clean Energy Academy: www.cleanenergyacademy.com

Forbidden Tech Book: www.forbiddentech.website

The post South African group refutes WHO’s declaration of an mpox emergency and warns the public about the risks of the vaccines appeared first on HopeGirl Blog.

For the second time in two years, WHO has declared mpox, formerly known as monkeypox, a public health emergency of international concern.  Below we look at whether WHO’s grounds for declaring an emergency are valid and what they will do next.

Our advice is do not comply and do not take the vaccine.

The World Health Organisation (“WHO”) first declared mpox a public health emergency of international concern (“PHEIC”) in July 2022.

On Wednesday, WHO Director-General Dr. Tedros Adhanom Ghebreyesus announced that the upsurge of mpox in the Democratic Republic of the Congo (“DRC”) and a growing number of countries in Africa constitutes a PHEIC under the International Health Regulations (2005).

Two vaccines already in use for mpox are recommended by WHO’s Strategic Advisory Group of Experts on Immunisation, and approved by authorities in Nigeria and the DRC.

Last week, the Director-General triggered the process for Emergency Use Listing for mpox vaccines, which will accelerate vaccine access for lower-income countries which have not yet issued their own national regulatory approval. Emergency Use Listing also enables partners including GAVI and UNICEF to procure vaccines for distribution.

World Health Organization (WHO) declares #mpox outbreak a Public Health Emergency of International Concern (PHEIC). pic.twitter.com/pAlOx9Bq13

— WHO Ghana (@WHOGhana) August 14, 2024

As The Conversation noted:

The spread of mpox through certain African countries led the Africa Centres for Disease Control and Prevention to declare earlier this week mpox a public health emergency of continental security. This is the first time the organisation has issued such an alert since it was established in 2017.

In 2022, an epidemic of mpox swept through non-endemic countries, including beyond Africa. This was a variant of clade II originating from Nigeria, called clade IIb. This was sexually transmitted, predominantly affecting men who have sex with men, and had a low fatality rate.

That epidemic peaked in 2022, with vaccines made available to people at risk in high-income countries, but there has been an uptick in 2024.

At the same time, large clade I epidemics were occurring in the Democratic Republic of the Congo, but with far less attention … most cases and deaths in the Democratic Republic of the Congo have been children. This means most transmission there is non-sexual and is likely to have occurred through close contact or respiratory aerosols.

WHO has declared mpox a global health emergency. What happens next? The Conversation, 15 August 2024

Unsafe Vaccines

The Conversation goes on to state the claims that the mpox variant in DRC is different from the rest of Africa where “vaccines were not available … even in 2023.”  DRC has clade I while other countries had clade IIb, for which vaccines were distributed.

The vaccines distributed are called Jynneos in some countries and Imvamune or Imvanex in others.  Jynneos is a smallpox vaccine which is claimed to be effective against mpox.  However, the smallpox vaccine is neither safe nor effective.

“Smallpox vaccine, when used routinely in babies, was considered the most dangerous vaccine available. It led to the deaths of several people per million administrations,” Dr. Meryl Nass warned when WHO declared mpox a PHEIC the first time.  In 2021, “the CDC perhaps inadvertently admitted it had no reliable evidence for either safety or efficacy [for the Jynneos vaccine],” she said.

A few months later Dr. Geert Vanden Bossche warned that young children should not be vaccinated with any type of smallpox vaccine. “The current monkeypox pandemic is to be considered an indirect consequence of the unfortunate covid mass vaccination programme … The monkeypox vaccination campaigns that are currently kicked off are not only likely to have a detrimental impact on individual health (particularly in covid unvaccinated children and vulnerable people) but should also be considered at risk of provoking a true public health emergency of international concern,” he said.

Related: The mantra “safe and effective” began with smallpox vaccines; were they “safe and effective”?

Jynneos is a live, attenuated vaccinia virus; Modified Vaccinia Ankara (“MVA”) virus which is an attenuated strain of the poxvirus Chorioallantois Vaccinia virus strain Ankara (“CVA”). CVA is not a naturally occurring virus, it was derived through serial passage in chicken embryo fibroblasts (“CEF”). The serial passages in CEF resulted in significant genetic changes to the original vaccinia virus strain Ankara.

The Ankara strain originated in Turkey.  In 1953, the vaccinia virus strain Ankara was brought from Turkey – where it had been propagated on the skin of calves and donkeys at the Turkish vaccine institute in Ankara for smallpox vaccine production – to the Institute for Infectious Diseases and Tropical Medicine at the University of Munich.  Herrlich and Mayr cultivated the virus on the chorioallantois membranes (“CAM”) of embryonated chicken eggs and therefore named it as Chorioallantois Vaccinia virus Ankara (“CVA”).  At the Bavarian State Institute for Vaccines, CVA was grown on the skin of calves to manufacture smallpox vaccine for the vaccination campaigns in Munich in 1954/1955.

Vaccinia virus, including CVA, is a member of the Poxviridae family.  Depending on the severity of the infection, the symptoms of a vaccinia virus infection include fever, general symptoms similar to those of a cold, local lymphadenopathy (swollen lymph nodes), small pock-like lesions throughout the skin and internal organs.  Quip Labs describes it as “similar to smallpox infection, though they are milder.”

In general, vaccinia virus infections are self-limiting and resolve on their own without specific treatment. However, in severe cases or among immunocompromised people, antiviral therapy and supportive care may be necessary.

Not only do the vaccines cause smallpox-like infections in vaccinated people but the infection may be spread to unvaccinated people.

In 2019, EMedicine noted: “As more smallpox vaccine becomes available, the safety of the live vaccine and the transmissibility of vaccinia virus from recently vaccinated person to susceptible host are the central issues debated.”

A 2010 paper published in the Brazilian Journal of Infectious Diseases stated: “The widespread use of [vaccinia] viruses in research laboratories and mass vaccination of militaries have contributed to increase the cases of those infections worldwide.”

Let’s remind ourselves what, according to WHO, are the symptoms of mpox:

The symptoms of the vaccinia virus infections from the mpox vaccine, Jynneos, and symptoms of mpox are very similar.

Misdiagnosis of Cases

“Testing capacity is low in the Democratic Republic of the Congo, most cases are not confirmed by lab testing, and the data we have are from a small sample of genomic sequences from the Kamituga region of South Kivu,” The Conversation said.

“Many countries do not have the capacity for widespread testing. So, we’ll have to rely on ‘suspected cases’, based on a clinical definition, to keep track of the epidemic,” the outlet added.

According to the World Health Organisation, mpox is characterised by a range of clinical features including rash, fever and enlarged lymph nodes.  The rash typically lasts for 2-4 weeks, with symptoms resolving on their own without treatment in most cases.  However, the symptoms being used to diagnose mpox are not unique.  Apart from vaccinia virus infections as mentioned above, there are similarities to chickenpox:

A further complication is that 20-30% of people with mpox may simultaneously have chickenpox, an unrelated infection that also causes a rash. So, an initial diagnosis of chickenpox (which is easier to test for) does not rule out mpox.

WHO has declared mpox a global health emergency. What happens next? The Conversation, 15 August 2024

Death Rates

WHO states: “According to available data, between 0.1% and 10% of people with mpox have died. It is important to note that death rates in different settings may differ due to several factors, such as access to health care and underlying immunosuppression.”

How WHO calculated the “death rate” has not been mentioned.  There are two ways to calculate the death rate of a virus.  One is the Case Fatality Rate (“CFR”) and the other the Infection Fatality Rate (“IFR”).  It is more likely that WHO has used the CFR which is typically higher than IFR, as it only considers deaths among diagnosed cases, whereas IFR includes deaths among all infected people, including those who may not have sought medical attention or been tested.

For examples of the exaggeration of death rates, we need look no further than covid.

The seasonal flu has an IFR of roughly 0.13% and affects those most severely who are chronically unwell. For covid, they grossly exaggerated the IFR and the number of deaths.

In July 2020, some claimed that covid was “around 50 to 100 times more lethal than the seasonal flu” with an IFR between 1.46% and 13.83%, depending on age.

In August 2020, WHO stated: “At this early stage of the pandemic, most estimates of fatality ratios have been based on cases detected through surveillance and calculated using crude methods, giving rise to widely variable estimates of CFR by country – from less than 0.1% to over 25%.”

In May 2020, prominent epidemiologist John Ioannidis published a preprint paper estimating the IFR for covid to be “relatively low,” less than 0.5% and possibly as low as 0.02%, which is comparable to the IFR of influenza.

In March 2021, Ioannidis conducted a systematic review of seroprevalence studies to estimate the IFR. They found an average global IFR of approximately 0.15%.

In October 2022, John Ioannidis published a study that estimated the IFR for covid as 0.035% for people aged 0-59 years and 0.095% for those aged 0-69 years.  “At a global level, pre-vaccination IFR may have been as low as 0.03% and 0.07% for 0-59 and 0-69 year old people, respectively,” the paper stated.

Related: Public Health Scotland reveals that Covid is no more deadly than seasonal flu

Adding to the unknown threat mpox poses is the inconclusive method of diagnosis of cases that is being used.  It begs the question of how WHO can declare a PHEIC based on so little proof.

Nevertheless, they are convinced, according to The Conversation, that “in the past month, the virus has spread to countries that share a border with the Democratic Republic of the Congo – Rwanda and Burundi. It has also spread to other East African countries, such as Kenya and Uganda. None of these countries have had mpox cases previously.”

What Happens Next?

Claiming that “a serious epidemic anywhere in the world is a concern for all of us, as it can spread globally through travel, as we saw with the covid pandemic,”  The Conversation describes what happens next: surveillance for its spread and open-source epidemic intelligence such as using AI to monitor trends in rash and fever illness.

As we noted earlier in this article, a rash and fever are not a conclusive diagnosis of mpox.  Surveillance likely includes testing people and wastewater to find “cases,” as they did with covid.

“Effective communication and tackling push-back against public health measures and disinformation is also key,” The Conversation said.  In other words, as we saw with covid, they intend to apply censorship, among other actions, to anyone who challenges WHO’s “official narrative.”

Now, WHO will coordinate the global mpox response, focusing on equity in disease prevention and access to diagnostics and vaccines. It is up to individual countries to do their best to comply with the International Health Regulations, and the protocols for how such a global emergency are managed.

WHO has declared mpox a global health emergency. What happens next? The Conversation, 15 August 2024

“Equity” in access to diagnostics and vaccines.  Equity is not equality.   “Equality” and “equity” are fundamentally different and the two concepts could not be more opposed.  Applied in this case it means they will be targeting certain populations with ineffective and unsafe vaccines.

Many hundreds of millions, if not billions, of people across the world do not want WHO with its unelected and unaccountable bureaucrats funded by the likes of Bill Gates to coordinate a global response to anything let alone dubious claims of an international mpox emergency.

Do not comply and do not take the vaccine.

Read more: WHO declares mpox a public health emergency again, Western Standard, 14 August 2024

Source:  https://expose-news.com/2024/08/18/who-declares-mpox-an-international-emergency/

Bitchute: https://www.bitchute.com/channel/YBM3rvf5ydDM/

Gab: https://gab.com/hopegirl

Telegram: https://t.me/Hopegirl587

EMF Protection Products: www.ftwproject.com

QEG Clean Energy Academy: www.cleanenergyacademy.com

Forbidden Tech Book: www.forbiddentech.website

The post WHO declares mpox an international emergency; on what grounds? appeared first on HopeGirl Blog.